GRAIL Inc (GRAL)

In the past six months, GRAIL's stock has experienced volatility influenced by clinical trial results, regulatory progress, and corporate announcements. In February 2026, the NHS-Galleri trial results led to a stock price drop, despite highlighting a reduction in Stage IV cancer diagnoses. In March 2026, shares increased after an analyst upgrade and the announcement of a new CEO. In April 2026, the stock saw fluctuations due to upcoming presentations, the CEO transition, the FDA PMA submission for Galleri, and its integration into the Epic Electronic Health Record platform. In May 2026, GRAIL reported strong first-quarter financial results and the FDA accepted its Premarket Approval application for the Galleri test.

The provided information does not explicitly detail demand seasonality for GRAIL, Inc.'s products and services. Demand for its tests is likely driven more by ongoing health awareness campaigns, physician recommendations, and insurance coverage rather than traditional seasonal consumer patterns. The company has reported consistent revenue growth and increasing test volumes, suggesting a steady increase in demand as it expands market penetration and regulatory approvals.

GRAIL, Inc. is a commercial-stage healthcare company focused on early cancer detection. Its mission is to alleviate the global burden of cancer by developing technology to detect multiple deadly cancer types in their earlier stages. GRAIL operates within the Biotechnology and Diagnostics & Research sectors of the Healthcare industry. GRAIL's primary product is Galleri, a multi-cancer early detection (MCED) blood test designed for asymptomatic individuals over 50. The company also offers diagnostic aid for cancer tests and provides development services. Additionally, GRAIL's precision oncology portfolio includes a RUO-targeted methylation-based platform for applications such as disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring.

GRAIL, Inc. is headquartered in Menlo Park, California, and has additional office locations in Washington, D.C., North Carolina (Durham/Raleigh), and London, UK. The company also has remote employees. GRAIL provides multi-cancer early detection testing and services in the United States and internationally.

GRAIL's brand reputation has been shaped by clinical trial outcomes and commercialization efforts for the Galleri test. The NHS-Galleri trial results impacted public and investor perception, while the FDA PMA submission for Galleri was a positive development. Integration with Epic is a significant step towards expanding access. Continued presentation of clinical data at medical conferences helps build scientific credibility. GRAIL has been recognized as a 'Best Place to Work', reflecting positively on its internal culture.

GRAIL, Inc. has a diverse ownership structure, with a significant portion held by institutional investors. As of May 7, 2026, GRAIL has 412 institutional owners and shareholders holding a total of 29,999,158 shares. Major institutional owners include BlackRock, Inc., Farallon Capital Management Llc, Baker Bros. Advisors Lp, Vanguard Group Inc, PRIMECAP Management Company, State Street Corp, Morgan Stanley, Illumina, Inc., and Sessa Capital (Master), L.P. Institutional ownership accounts for approximately 66.56% of the company's shares. Insiders hold approximately 1.85% to 19.77% of the stock.